Cryptococcus neoformans neutralizes macrophage and astrocyte derived nitric oxide without interfering with inducible nitric oxide synthase induction or catalytic activity - Possible involvement of nitric oxide consumption

Scandinavian Journal of Immunology

Volumn 51, Issue 4, 2000, Pages 384-391

  Trajkovic, V ^a   Stepanovic, Srdjan ^a   Samardzic, T ^b   Jankovic, V ^a   Badovinac, V ^b   Mostarica Stojkovic, M ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SCAVENGER;

ANIMAL CELL; ARTICLE; ASTROCYTE; CATALYSIS; CELL KILLING; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; ENZYME INDUCTION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RAT; YEAST CELL;

EID: 0033993942     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2000.00683.x     Document Type: Article

References (27)

1. MacMicking J, Xie Q-W, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-50.
2. Liew FY. Regulation of lymphocyte functions by nitric oxide. Curr Opin Immunol 1995;17:396-9.
3. Alspaugh JA, Granger DL. Inhibition of Cryptococcus neoformans replication by nitrogen oxide supports the role of these molecules as effectors of macrophage-mediated cytostasis. Infect Immun 1991; 7:2291-6.
4. Lee SC, Dickson DW, Brosnan CF, Casadevall A. Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism. J Exp Med 1994;180:365-9.
5. Tohyama M, Kawakami K, Futenma M, Saito A. Enhancing effect of oxygen radical scavengers on murine macrophage anticryptococcal activity through production of nitric oxide. Clin Exp Immunol 1996;103:436-41.
6. Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ. Cryptococcal diseases in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann Intern Med 1986;104:234-40.
7. Lovchik JA, Lyons CR, Lipscomb MF. A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am J Respir Cell Mol Biol 1995;13:116-24.
8. Bulmer GS, Tacker JR. Phagocytosis of Cryptococcus neoformans by alveolar macrophages. Infect Immun 1975;11:73-9.
9. Xie Q, Kawakami K, Kudeken N, Zhang T, Qureshi MH, Saito A. Different susceptibility of three clinically isolated strains of Cryptococcus neoformans to the fungicidal effects of reactive nitrogen and oxygen intermediates: possible relationships with virulence. Microbiol Immunol 1997;41:725-31.
10. Porebska-Budny M, Sakina NL, Stepien KB, Dontsov AE, Wilczok T. Antioxidative activity of synthetic melanins. Cardiolipin liposome model. Biochim Biophys Acta 1992;1116:11-6.
11. Wang Y, Casadevall A. Susceptibility of melanized and non-melanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect Immun 1994;62:3004-7.
12. Naslund PK, Miller WC, Granger DL. Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect Immun 1995;63:1298-304.
13. Kawakami K, Zhang T, Qureshi MH, Saito A. Cryptococcus neoformans inhibits nitric oxide production by murine peritoneal macrophages stimulated with interferon-gamma and lipopolysaccharide. Cell Immunol 1997;180:47-54.
14. Warren NG, Hazen KC. Candida, Cryptococcus and other yeasts of medical importance. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology, 6th edn. Washington DC: ASM Press, 1995: 723-37.
15. Hattori Y, Nakanishi N. Effects of cyclosporin A and FK506 on nitric oxide and tetrahydrobiopterin synthesis in bacterial lipopolysaccharide-treated J774 macrophages. Cell Immunol 1995;165:7-11.
16. Hibbs JB, Taintor R, Vavrin Z, Rachlin E. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1989;157:87-94.
17. Takahashi GW, Montgomery RB, Stahl WL et al. Pentoxifylline inhibits tumour necrosis factor-α mediated cytotoxicity and cytostasis in L929 murine fibrosarcoma cells. Int J Immunopharmacol 1994; 16:723-36.
18. Feinstein DL, Galea E, Roberts S, Berquist H, Wang H, Reis DJ. Induction of nitric oxide synthase in rat C6 glioma cells. J Neurochem 1994;62:315-21.
19. Misko TP, Moore WM, Kasten TP et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993;233:119-25.
20. Albina JE, Mills CD, Henry WL, Caldwell MD. Regulation of macrophage physiology by 1-arginine: role of the oxidative 1-arginine deiminase pathway. J Immunol 1989;143:3641-6.
21. Trajkovic V, Badovinac V, Popadic D, Hadzic O, Stojkovic MM. Cell-specific effects of pentoxifylline on nitric oxide production and inducible nitric oxide synthase mRNA expression. Immunology 1997;92:402-6.
22. Trajkovic V, Badovinac V, Jankovic V, Mostarica Stojkovic M. Cyclosporin A inhibits activation of inducible nitric oxide synthase in C6 glioma cell line. Brain Res 1999;816:92-8.
23. Pietraforte D, Mallozi C, Scorza G, Minetti M. Role of thiols in the targeting of S-nitroso thiols to red blood cells. Biochemistry 1995; 34:7177-85.
24. Chinen T, Qureshi MH, Koguchi Y, Kawakami K. Candida albicans suppresses nitric oxide (NO) production by interferon-gamma (IFN-γ) and lipopolysaccharide (LPS) stimulated murine peritoneal macrophages. Clin Exp Immunol 1999;115:491-7.
25. Crawford MJ, Sherman DR, Goldberg DE. Regulation of Saccharomyces cerevisiae flavohemoglobin gene expression. J Biol Chem 1995;270:6991-6.
26. Wennmalm A, Benthin G, Petersson AS. Dependence of the metabolism of nitric oxide (NO) in healthy human whole blood on the oxygenation of its red cell haemoglobin. Br J Pharmacol 1992; 106:507-8.
27. Membrillo-Hernandez J, Coopamah MD, Anjum MF et al. The flavohemoglobin of Escherichia coli confers resistance to a nitrosating agent, a 'Nitric oxide releaser,' and paraquat and is essential for transcriptional responses to oxidative stress. J Biol Chem 1999;274:748-54.